MX2017008917A - Agentes de ligacion agonistas del receptor tnf. - Google Patents

Agentes de ligacion agonistas del receptor tnf.

Info

Publication number
MX2017008917A
MX2017008917A MX2017008917A MX2017008917A MX2017008917A MX 2017008917 A MX2017008917 A MX 2017008917A MX 2017008917 A MX2017008917 A MX 2017008917A MX 2017008917 A MX2017008917 A MX 2017008917A MX 2017008917 A MX2017008917 A MX 2017008917A
Authority
MX
Mexico
Prior art keywords
receptor binding
binding agents
tnf receptor
agonistic
agonistic tnf
Prior art date
Application number
MX2017008917A
Other languages
English (en)
Other versions
MX377773B (es
Inventor
Sahin Ugur
GIESEKE Friederike
Altintas Isil
Satijn David
Parren Paul
Original Assignee
Biontech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Ag filed Critical Biontech Ag
Publication of MX2017008917A publication Critical patent/MX2017008917A/es
Publication of MX377773B publication Critical patent/MX377773B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a agentes de ligación que se ligan a receptores de la superfamilia TNF, en particular a agentes de ligación que se ligan a al menos dos receptores diferentes de la superfamilia TNF, así como a su uso en la medicina. La presente invención se refiere además a moléculas de ácido nucleico que codifican estos agentes de ligación, a células que comprenden estas moléculas de ácido nucleico y/o composiciones farmacéuticas y kit.
MX2017008917A 2015-01-08 2016-01-08 Agentes de ligacion agonistas del receptor tnf. MX377773B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2015050255 2015-01-08
PCT/EP2016/050308 WO2016110584A1 (en) 2015-01-08 2016-01-08 Agonistic tnf receptor binding agents

Publications (2)

Publication Number Publication Date
MX2017008917A true MX2017008917A (es) 2018-02-09
MX377773B MX377773B (es) 2025-03-11

Family

ID=55072677

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017008917A MX377773B (es) 2015-01-08 2016-01-08 Agentes de ligacion agonistas del receptor tnf.
MX2024012093A MX2024012093A (es) 2015-01-08 2017-07-05 Agentes de ligacion agonistas del receptor tnf.
MX2020012240A MX2020012240A (es) 2015-01-08 2017-07-05 Agentes de ligacion agonistas del receptor tnf.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2024012093A MX2024012093A (es) 2015-01-08 2017-07-05 Agentes de ligacion agonistas del receptor tnf.
MX2020012240A MX2020012240A (es) 2015-01-08 2017-07-05 Agentes de ligacion agonistas del receptor tnf.

Country Status (25)

Country Link
US (4) US10457735B2 (es)
EP (3) EP3242890B1 (es)
JP (4) JP6744326B2 (es)
KR (3) KR102640769B1 (es)
CN (3) CN111499752B (es)
AU (2) AU2016205974B2 (es)
BR (1) BR112017013189B1 (es)
CA (2) CA3224830A1 (es)
CY (2) CY1122399T1 (es)
DK (2) DK3623386T3 (es)
ES (2) ES2922398T3 (es)
HR (2) HRP20191824T1 (es)
HU (2) HUE048532T2 (es)
LT (1) LT3623386T (es)
ME (1) ME03576B (es)
MX (3) MX377773B (es)
PL (2) PL3623386T3 (es)
PT (2) PT3623386T (es)
RS (2) RS63384B1 (es)
RU (1) RU2723131C2 (es)
SG (2) SG11201704597WA (es)
SI (2) SI3242890T1 (es)
SM (2) SMT201900702T1 (es)
WO (1) WO2016110584A1 (es)
ZA (1) ZA201704797B (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
CN105051069B (zh) 2013-01-14 2019-12-10 Xencor股份有限公司 新型异二聚体蛋白
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
KR102497443B1 (ko) 2014-03-28 2023-02-08 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CA2967426A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
PH12017502013B1 (en) 2015-05-07 2022-07-22 Agenus Inc Anti-ox40 antibodies and methods of use thereof
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
RU2018139339A (ru) * 2016-04-22 2020-05-22 Эллигейтор Биосайенс Аб Новые биспецифические полипептиды против cd137
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
MX2018016265A (es) 2016-06-28 2019-07-04 Xencor Inc Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
CA3030636A1 (en) 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
IL265046B2 (en) * 2016-08-30 2025-04-01 Xencor Inc Bispecific immunomodulatory antibodies that bind to costimulatory and checkpoint receptors
CN109983033B (zh) * 2016-09-23 2023-10-31 美勒斯公司 调节细胞表达的生物活性的结合分子
EP3538152A4 (en) 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
WO2018134787A2 (en) 2017-01-20 2018-07-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd137+ cells
US20200087410A1 (en) * 2017-03-29 2020-03-19 Glycotope Gmbh Humanized anti-cd40 antibodies
CA3070272A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
WO2019025545A1 (en) * 2017-08-04 2019-02-07 Genmab A/S BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3676294A4 (en) * 2017-08-28 2021-12-22 Systimmune, Inc. ANTI-CD3 ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR20200085828A (ko) 2017-11-08 2020-07-15 젠코어 인코포레이티드 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
EP3728302A1 (en) 2017-12-19 2020-10-28 Xencor, Inc. Engineered il-2 fc fusion proteins
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
KR20210003814A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
US12344672B2 (en) 2018-07-12 2025-07-01 Invox Pharma Limited Antibody molecules that bind PD-L1 and CD137
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
JP7598312B2 (ja) 2018-07-23 2024-12-11 ハイデルベルク ファーマ リサーチ ゲーエムベーハー 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
MX2021003765A (es) 2018-10-03 2021-07-15 Xencor Inc Proteínas il-12 de fusión a fc heterodimérico.
CN112805299B (zh) 2018-10-05 2025-09-16 西雅图儿童医院以西雅图儿童研究机构名义经营 针对原发性免疫缺陷、胱氨酸病和威尔逊病的新生儿筛查
MA54139A (fr) 2018-11-06 2021-09-15 BioNTech SE Formulation d'anticorps
JP7463366B2 (ja) * 2018-11-20 2024-04-08 タケダ ワクチン，インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
WO2021156326A1 (en) 2020-02-04 2021-08-12 Genmab A/S Antibodies for use in therapy
US11940448B2 (en) 2020-03-31 2024-03-26 Seattle Children's Hospital Proteomic screening for lysosomal storage diseases
US12523662B2 (en) 2020-04-02 2026-01-13 Seattle Children's Hospital Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
JP7773528B2 (ja) 2020-08-19 2025-11-19 ゼンコア インコーポレイテッド 抗ｃｄ２８組成物
WO2022081900A1 (en) * 2020-10-15 2022-04-21 Bioincept, Llc Systems, compositions and methods of determining viability of embryos using the same
CN112175080B (zh) * 2020-10-22 2021-05-25 优睿赛思(武汉)生物科技有限公司 抗人白介素-6高亲和力兔单克隆抗体及应用
AU2021393908A1 (en) 2020-12-07 2023-06-22 BioNTech SE Antibody and taxane combination therapy
KR20230169135A (ko) * 2021-03-09 2023-12-15 젠맵 에이/에스 치료에 있어서 cd40 및 cd137에 대한 다중특이 결합제
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
CN115433277A (zh) * 2021-06-05 2022-12-06 苏州缔码生物科技有限公司 抗cd38兔重组单克隆抗体的制备及应用
BR112023027006A2 (pt) 2021-06-21 2024-03-12 BioNTech SE Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação
US20240059782A1 (en) * 2022-03-01 2024-02-22 Agilent Technologies, Inc. Anti-human b cell maturation antigen (bcma) antibodies and their use in immunohistochemistry (ihc)
WO2024050318A1 (en) * 2022-08-27 2024-03-07 H. Lee Moffitt Cancer Center And Research Institute Cd40l 41bbl bispecific proteins
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
CN117069848B (zh) * 2023-08-02 2025-02-28 武汉爱博泰克生物科技有限公司 抗人cd146兔单克隆抗体及其应用
TW202540189A (zh) 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體
CN118440198B (zh) * 2024-04-03 2024-11-15 武汉爱博泰克生物科技有限公司 抗人cd69蛋白的兔单克隆抗体及其应用
CN118620078B (zh) * 2024-07-09 2024-11-19 武汉爱博泰克生物科技有限公司 抗人cd45ra蛋白的抗体、抗体偶联物及其应用
CN118453854B (zh) * 2024-07-12 2024-10-29 广州粤华制药有限公司 一种用于建立慢性肾小球肾病模型的组合物及其应用
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
CN119431591B (zh) * 2024-12-16 2025-08-05 无锡傲锐东源生物科技有限公司 抗人psp蛋白的单克隆抗体及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2467242A1 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
CN101023102B (zh) * 2004-09-17 2013-05-29 霍夫曼-拉罗奇有限公司 抗-ox40l抗体
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
GEP20135917B (en) * 2006-03-17 2013-09-10 Biogen Idec Inc Stabilized polypeptide compositions
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
CA2679399A1 (en) * 2007-02-27 2008-09-04 Genetech, Inc. Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
EP2139924B1 (en) 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
ES2573458T3 (es) 2007-09-14 2016-06-08 Vrije Universiteit Brussel Mejoramiento de la capacidad estimulatoria de las células T de las células que presentan antígeno humano y su uso en vacunación
HUE032735T2 (en) * 2007-12-14 2017-10-30 Bristol Myers Squibb Co Binding molecules for the human OX40 receptor
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
EP2398498B1 (en) * 2009-02-17 2018-09-05 UCB Biopharma SPRL Antibody molecules having specificity for human ox40
CA2804550C (en) 2010-07-09 2021-01-05 Bionovion Holding B.V. Agonistic antibody to cd27
JP5828909B2 (ja) 2011-01-10 2015-12-09 シーティー アトランティック リミテッド 腫瘍関連抗原結合抗体を含む併用療法
EP2731677B1 (en) * 2011-07-11 2018-04-18 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
KR101685262B1 (ko) * 2011-08-23 2016-12-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｏｘ４０ 항체 및 이의 사용 방법
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
NZ712903A (en) * 2013-03-18 2018-07-27 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
CA3030636A1 (en) * 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137

Also Published As

Publication number Publication date
RU2017127792A3 (es) 2019-06-17
LT3623386T (lt) 2022-08-10
KR102640769B1 (ko) 2024-02-27
HUE059219T2 (hu) 2022-10-28
EP4071176A3 (en) 2022-12-14
CY1125349T1 (el) 2025-05-09
US20200079866A1 (en) 2020-03-12
HUE048532T2 (hu) 2020-07-28
EP4071176A2 (en) 2022-10-12
US11814411B2 (en) 2023-11-14
EP3623386A1 (en) 2020-03-18
PL3242890T3 (pl) 2020-04-30
US20240254249A1 (en) 2024-08-01
HRP20191824T1 (hr) 2020-01-24
NZ733157A (en) 2021-10-29
PL3623386T3 (pl) 2022-08-08
CY1122399T1 (el) 2020-11-25
JP7487376B2 (ja) 2024-05-20
RS63384B1 (sr) 2022-08-31
ES2755527T3 (es) 2020-04-22
JP2018506298A (ja) 2018-03-08
BR112017013189B1 (pt) 2024-03-05
CN109476761A (zh) 2019-03-15
US10927181B2 (en) 2021-02-23
US12421319B2 (en) 2025-09-23
KR102238326B1 (ko) 2021-04-12
JP6744326B2 (ja) 2020-08-19
US20210253725A1 (en) 2021-08-19
SI3242890T1 (sl) 2020-01-31
DK3623386T3 (da) 2022-07-04
SMT202200288T1 (it) 2022-09-14
MX2020012240A (es) 2021-02-22
RU2723131C2 (ru) 2020-06-08
EP3623386B1 (en) 2022-04-13
KR20170132717A (ko) 2017-12-04
CA2969888A1 (en) 2016-07-14
ZA201704797B (en) 2019-05-29
AU2016205974A1 (en) 2017-07-13
JP2022025064A (ja) 2022-02-09
CA3224830A1 (en) 2016-07-14
EP3242890A1 (en) 2017-11-15
KR20240028548A (ko) 2024-03-05
MX2024012093A (es) 2024-11-08
RU2017127792A (ru) 2019-02-08
JP7390345B2 (ja) 2023-12-01
ME03576B (me) 2020-07-20
SG11201704597WA (en) 2017-07-28
SG10202003171TA (en) 2020-05-28
HRP20220811T1 (hr) 2022-09-30
RS59693B1 (sr) 2020-01-31
AU2022200571B2 (en) 2024-11-21
US20180194849A1 (en) 2018-07-12
AU2022200571A1 (en) 2022-02-17
CN117843799A (zh) 2024-04-09
PT3623386T (pt) 2022-07-18
JP6950056B2 (ja) 2021-10-13
JP2020188797A (ja) 2020-11-26
US10457735B2 (en) 2019-10-29
KR20210041634A (ko) 2021-04-15
CN109476761B (zh) 2020-01-10
WO2016110584A1 (en) 2016-07-14
BR112017013189A2 (pt) 2018-04-10
ES2922398T3 (es) 2022-09-14
CN111499752B (zh) 2024-05-31
MX377773B (es) 2025-03-11
DK3242890T3 (da) 2019-10-21
SI3623386T1 (sl) 2022-09-30
RU2020115901A (ru) 2020-08-05
CN111499752A (zh) 2020-08-07
AU2016205974B2 (en) 2021-11-04
PT3242890T (pt) 2019-12-10
JP2023085435A (ja) 2023-06-20
SMT201900702T1 (it) 2020-01-14
EP3242890B1 (en) 2019-09-04
KR102838719B1 (ko) 2025-07-28

Similar Documents

Publication Publication Date Title
MX2017008917A (es) Agentes de ligacion agonistas del receptor tnf.
CY1121876T1 (el) Συνθεσεις παρακαμψης εξωνιου για τη θεραπεια της μυϊκης δυστροφiας
BR112016001036A2 (pt) fusocinas envolvendo citocinas com afinidades de ligação de receptores fortemente reduzida
CL2014001254A1 (es) Molécula de unión biespecífica para bcma y cd3; secuencia de ácido nucleico que la codifica; vector ; célula; composición farmacéutica que comprende a la molécula de unión; uso para tratar enfermedades relacionadas a transtornos de células plasmáticas, trastornos de células b correlacionados con la expresión de bcma y enfermedades autoinmunes.
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
CY1118014T1 (el) Aνti-il-23 αντισωματα
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
CL2014000631A1 (es) Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
MX385926B (es) Proteínas de fusión de citoquinas.
PE20160193A1 (es) Diacuerpos monovalentes biespecificos que pueden unirse a gpa33 y cd3, y usos
BR112016004324A2 (pt) anticorpos
AR090923A1 (es) Anticuerpos anti-il-23
UY35407A (es) ?PROTEÍNAS DE FUSIÓN COMPRENDIENDO PORCIONES PDGF y VEGF DE UNIÓN Y MÉTODOS PARA SU USO?.
EA201890078A1 (ru) Антитело
CL2015000532A1 (es) Molécula de enlace a interleuquina 18 (il-18); anticuerpo; polinucleótido que lo codifica; vector; célula huésped; composición farmacéutica; uso para tratar sarcoidosis y otras inmunodeficiencias; y kit de diagnóstico.
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
CL2014003167A1 (es) Molécula de unión que se une específicamente a inteleuquina 6 (il-6); composición farmacéutica que la comprende; ácido nucleico; vector; célula huésped; y uso para tratar enfermedad o trastorno asociado a il-6.
ECSP18008922A (es) Anticuerpos anti-CD154 y métodos de uso de estos
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
UY36561A (es) Nuevas proteínas específicas para pioverdina y pioquelina
DK3200822T3 (da) Bindingsmolekyler, i særdeleshed antistoffer, der binder til l1cam (cd171)
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
BR112014025560A2 (pt) anticorpos anti-pdgf-c

Legal Events

Date Code Title Description
FG Grant or registration